Shots:

• The CHMP’s recommendation is based on Phase III IMpower110 study assessing Tecentriq vs CT  in 572 PD-L1-selected- CT-naïve participants in a ratio (1:1) with stage IV non-squamous or squamous NSCLC
• Results: OS in people with high PD-L1 expression (7.1 vs 3.1mos.); safety profile is consistent with the current profile & no new safety signals were identified
• If approved- Tecentriq could provide people with a specific type of lung cancer a chemotherapy-free option in the 1L treatment setting

­ Ref: Roche | Image: Roche